Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Mediastinal Large B-cell Lymphoma: early-phase trial registry

A small indexed set (3 trials) with no open enrollment listed right now.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count

Mediastinal Large B-cell Lymphoma: 3 US clinical trials tracked, none currently recruiting.

Mediastinal Large B-cell Lymphoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Nebraska, running 1 of these trials.

Enrollment posture brief

Registry condition mediastinal-large-b-cell-lymphoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Mediastinal Large B-cell (th…0%
Open-enrollment share among volume-matched conditions near Mediastinal Large B-cell Lymphoma

Mediastinal Large B-cell Lymphoma has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mediastinal Large B-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mediastinal Large B-cell Lymphoma is recruiting below its size-band peers.

    0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Mediastinal Large B-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Adaptive Bridging Radiation Therapy (ABRT) Radiation
1 trials
Post-infusion radiation Radiation
1 trials
Bridging radiation therapy Radiation
1 trials
19(T2)28z1xx TRAC T cell Biological
1 trials
Liso-cel Biological
1 trials

US sites by state

Facility locations filed on Mediastinal Large B-cell Lymphoma trials. A trial with sites in several states counts in each.

New York 1 trials
Nebraska 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Mediastinal Large B-cell Lymphoma page

3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Mediastinal Large B-cell Lymphoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • University of Nebraska sponsors the most Mediastinal Large B-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See University of Nebraska's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mediastinal Large B-cell Lymphoma condition card totals 3 registered trials; most-linked intervention Adaptive Bridging Radiation Therapy (ABRT); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.